Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals Ltd. submitted a Rule 144 notice reporting proposed sale of Class A ordinary shares related to an Employee Stock Option Exercise dated 03/09/2026. The filing lists 36,722 shares in the securities-to-be-sold row and discloses prior sales by Mark Ragosa of 12,000 shares on 01/08/2026 and 17,845 shares on 02/09/2026, with corresponding proceeds of $502,628.00 and $772,311.00.
FMR LLC reports beneficial ownership in Kiniksa Pharmaceuticals International plc Class A common stock. The filing shows FMR LLC (and Abigail P. Johnson in related capacity) beneficially owns 4,854,354.23 shares, equal to 10.6% of the class as reported with a 02/27/2026 reference. The cover lists sole voting power of 4,852,623 shares and sole dispositive power of 4,854,354.23 shares. The schedule includes an Exhibit 99 13d-1(k)(1) agreement and signatures by an authorized representative on 03/05/2026.
Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini exercised options and sold shares of Class A Ordinary Shares. He exercised a fully vested option for 40,000 Share Options at an exercise price of $10.36 per share, acquiring 40,000 Class A Ordinary Shares on March 2, 2026. That same day, he sold a total of 40,000 Class A Ordinary Shares in open-market transactions at weighted average prices ranging from about $43.555 to $46.09, under a Rule 10b5-1 plan executed on November 18, 2025. After these transactions, he directly holds 61,324 Class A Ordinary Shares and 58,424 Share Options.
Kiniksa Pharmaceuticals, Ltd. submitted a Rule 144 notice reporting the sale of 40,000 Class A ordinary shares on 03/02/2026. The transaction is described as an employee stock option exercise settled as a broker payment for a cashless exercise through Charles Schwab & Co., Inc..
Kiniksa Pharmaceuticals International, plc reports its annual business overview, highlighting a commercial rare-disease franchise and a focused cardiovascular pipeline. The company markets ARCALYST, an IL‑1α/IL‑1β cytokine trap, as the first and only FDA‑approved therapy for recurrent pericarditis, targeting an estimated 40,000 treated patients in the United States.
Kiniksa is advancing KPL‑387, an IL‑1 receptor monoclonal antibody with FDA Orphan Drug Designation for pericarditis, through a Phase 2/3 recurrent pericarditis program, with Phase 2 data expected in the second half of 2026. Preclinical KPL‑1161 aims for quarterly dosing, while development of abiprubart in Sjögren’s Disease has been discontinued as the company explores strategic options for the asset.
The business model combines internal development with partnerships. Kiniksa evenly splits ARCALYST profits and certain proceeds with Regeneron, has out‑licensed vixarelimab to Genentech with potential milestones and royalties, and granted Huadong rights to ARCALYST in a broad Asia‑Pacific territory. Intellectual property protection extends across composition, methods of use and formulations, supplemented by U.S. and EU regulatory exclusivities.
Kiniksa Pharmaceuticals International, plc reported a strong turnaround in 2025, moving to profitability on rapid ARCALYST growth. Net product revenue reached $202.1 million in the fourth quarter and $677.6 million for the year, a 62% increase driven by adoption in recurrent pericarditis.
The company generated 2025 net income of $59.0 million, or $0.80 per basic share, compared with a net loss of $43.2 million in 2024. Total 2025 revenue was $677.6 million against operating expenses of $600.3 million, leading to income from operations of $77.2 million.
Kiniksa ended 2025 with $414.1 million in cash, cash equivalents, and short-term investments, up $170.4 million year over year. Management expects ARCALYST 2026 net product revenue of $900–$920 million and highlighted pipeline milestones, including Phase 2 KPL-387 data expected in the second half of 2026 and a planned Phase 1 start for KPL-1161 by the end of 2026.
Kiniksa Pharmaceuticals International, plc received an updated ownership disclosure showing that investment adviser Rubric Capital Management LP and David Rosen together report beneficial ownership of 3,328,653 Class A ordinary shares, representing 7.37% of the class, based on 45,161,019 shares outstanding as of October 24, 2025.
The reporting parties indicate they have shared voting and dispositive power over these shares, which are held through funds they advise, including Rubric Capital Master Fund LP. They certify the position is held in the ordinary course of business and not with the purpose or effect of changing or influencing control of Kiniksa.
Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in February 2026 under a pre‑arranged Rule 10b5‑1 trading plan executed on September 11, 2025.
On February 10 and February 12, Barry exercised share options at an exercise price of $15.47 per Class A ordinary share and immediately sold the resulting shares in open-market transactions at $45 per share. Across both dates, 2,800 Class A ordinary shares were sold while maintaining 12,546 Class A ordinary shares held directly after the reported transactions. The options involved were fully vested and exercisable.
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa reported option exercises and share sales in the company’s Class A ordinary shares. On February 9, 2026, he exercised options for 8,374 shares at $12.97 and 2,471 shares at $16.90, converting them into the same number of shares.
On the same date, he sold 9,114 shares at a weighted average price of $42.85 and 8,731 shares at a weighted average price of $43.72 through a broker-dealer in multiple trades. These transactions were effected under a Rule 10b5-1 trading plan executed on August 14, 2025. After these trades, he directly held 12,086 Class A ordinary shares.
Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in early February 2026 under a pre-arranged trading plan. On February 2, 3, and 4, he exercised fully vested share options at an exercise price of $15.47 per Class A Ordinary Share and sold the resulting shares in open-market transactions at weighted average prices of $45.00, $45.27, and $45.02, respectively.
The transactions were effected pursuant to a Rule 10b5-1 plan executed on September 11, 2025. After these trades, he directly beneficially owned 12,546 Class A Ordinary Shares and 2,800 share options that are fully vested and exercisable.